Safety and efficacy of intralipid emulsions of amphotericin B

Journal of Antimicrobial Chemotherapy

Volumn 38, Issue 3, 1996, Pages 333-347

  Sievers, Theodore M ^a   Kubak, Bernard M ^a   Wong Beringer, Annie ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; INTRALIPID;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG STABILITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MYCOSIS; NEPHROTOXICITY; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CLINICAL TRIALS; CRYPTOCOCCUS; DRUG EVALUATION; FAT EMULSIONS, INTRAVENOUS; HUMANS; MICE; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS;

EID: 0029819092     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/38.3.333     Document Type: Review

References (25)

1. Anderson, R. P. & Clark, D. A. (1995). Amphotericin B toxicity reduced by administration in fat emulsion. Annals of Pharmacotherapy 29, 496-500.
2. Branch, R. A. (1988). Prevention of amphotericin B induced renal impairment. Archives of Internal Medicine 148, 2389-94.
3. Caillot, D., Casasnovas, O., Solary, E., Chavanet, P., Bonnette, B., Reny, G. et al. (1993). Efficacy and tolerance of an amphotericin B lipid (Intralipid) emulsion in the treatment of candidaemia in neutropenic patients. Journal of Antimicrobial Chemotherapy 31, 161-9.
4. Caillot, D., Chavanet, P., Casasnovas, O., Solary, E., Zanetta, G., Buisson, M. et al. (1992). Clinical evaluation of a new lipid-based delivery system for intravenous administration of amphotericin B. European Journal of Clinical Microbiology and Infectious Disease 11, 22-5.
5. Caillot, D., Reny, G., Solary, E., Casasnovas, O., Chavanet, P., Bonnette, B. et al. (1994). A controlled trial of the tolerance of amphotericin B infused in dextrose or in Intralipid in patients with haematological malignancies. Journal of Antimicrobial Chemotherapy 33, 603-13.
6. Chavanet, P. & Caillot, D. (1995). Lipid-based formulations of amphotericin B. Journal of Antimicrobial Chemotherapy 35, 711-3.
7. Chavanet, P., Garry, I., Charlier, N., Caillot, D., Kisterman, J.-P., D'Athis, M. et al. (1992). Trial of glucose versus fat emulsion preparation of amphotericin for use in HIV infected patients with candidiasis. British Medical Journal 305, 921-5.
8. de Marie, S., Janknegt, R. & Bakker-Woudenberg, I. A. J. M. (1994). Clinical use of liposomal and lipid-complexed amphotericin B. Journal of Antimicrobial Chemotherapy 33, 907-16.
9. Gallis, H. A., Drew, R. H. & Rickard, W. W. (1990). Amphotericin B: 30 years of clinical experience. Reviews of Infectious Disease 12, 308-29.
10. Janknegt, R., de Marie, S., Bakker-Woudenberg, I. A. J. M. & Crommelin, D. J.-A. (1992). Liposomal and lipid formulations of amphotericin B. Clinical Pharmacokinetics 23, 279-91.
11. Joly, V., Farinotti, R., Saint-Julien, L., Chéron, M., Carbon, C. & Yeni, P. (1994). In vitro renal and in vivo therapeutic efficacy in experimental murine cryptococcosis of amphotericin B (Fungizone) associated with Intralipid. Antimicrobial Agent and Chemotherapy 38, 177-83.
12. Kirsh, R., Goldstein, R., Tarloff, J., Parris, D., Hook, J., Hana, N. et al. (1988). An emulsion formulation of amphotericin B improves the therapeutic index when treating systemic murine candidiasis. Journal of Infectious Diseases 158, 1065-70.
13. Lamb, K. A., Washington, C., Davis, S. S. & Denyer, S. P. (1991). Toxicity of amphotericin B to cultured canine kidney cell monolayers. Journal of Pharmacy and Pharmacology 43, 522-4.
14. Leake, H. A., Appleyard, M. N., & Hartley, J. P. (1994). Successful treatment of resistant cryptococcal meningitis with amphotericin B lipid emulsion after nephrotoxicity with conventional intravenous amphotericin B. Journal of Infection 28, 319-22.
15. Lyman, C. A. & Walsh, T. J. (1992). Systemically administered antifungal agents. Drugs 44, 9-35.
16. Macedo, M. C., Dulley, F. L., Ostronoff, M., Machado, C. M., Zambon, E., Matsumoto, C. et al. (1994). Effectiveness of amphotericin B in lipid emulsion for treating fungal septicemia in granulocytopenic patients. Clinical Infectious Disease 19, 366-7.
17. Maddux, M. S. & Barriere, S. (1980). A review of complications of amphotericin-B therapy: recommendations for prevention and management. Drug Intelligence and Clinical Pharmacy 14, 177-81.
18. Meunier, F. (1994). Alternative modalities of administering amphotericin B: current issues. Journal of Infection 28, Suppl. 1, 51-6.
19. Moreau, P., Milpied, N., Fayette, N., Ramée, J.-F. & Harousseau, J.-L. (1992). Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with Intralipid compared with conventional amphotericin B in neutropenic patients. Journal of Antimicrobial Chemotherapy 30, 535-41.
20. Smith, T. M. & Strozyk, W. R. (1994). Lack of toxicity with the administration of amphotericin B in a lipid emulsion. Annals of Pharmacotherapy 28, 1307-8.
21. Swenson, C. E., Bolcsak, L. E., Perkins, W. R. & Janoff, A. S. (1995). Lipid-based formulations of amphotericin B. Journal of Antimicrobial Chemotherapy 35, 709-11.
22. Trissel, L. (1994). Amphotericin B. In Handbook on Injectable Drugs, 8th edn, pp. 67-72. American Society Hospital Pharmacists, Bethesda, MD.
23. Trissel, L. (1995). Amphotericin B does not mix with fat emulsion. American Journal of Health-System Pharmacists 52, 1463-4.
24. Vita, E. & Schroeder, D. J. (1994). Intralipid prophylaxis of amphotericin B nephrotoxicity. Annals of Pharmacotherapy 28, 1182-3.
25. Washington, C., Lance, M. & Davis, S. S. (1993). Toxicity of amphotericin B emulsion formulations. Journal of Antimicrobial Chemotherapy 31, 806-8.